Clinical trials in DO NOT EDIT

Clinical research in the city targets systemic lupus erythematosus, evaluating novel immunomodulatory agents to improve patient outcomes.

• Safety and tolerability assessment of the investigational biologic
• Pharmacokinetic and pharmacodynamic profiling over time
• Impact on disease activity indices and flare frequency
• Exploration of patient‑reported quality of life measures

Ongoing recruitment reflects a strong local commitment to advancing therapies for autoimmune conditions.

Studies focus on solid tumours, particularly hormone‑responsive breast cancer, testing a targeted inhibitor of the AKT/PI3K/PTEN pathway.

• Dose‑finding and maximum tolerated dose determination
• Combination with estrogen receptor antagonists or degraders
• Biomarker‑guided patient enrollment based on pathway alterations
• Preliminary evaluation of anti‑tumor activity and response rates

The trials aim to define optimal dosing and early efficacy while engaging a dedicated local investigator.

The city hosts two actively recruiting studies across immune and oncology therapeutic areas, illustrating a focused but expanding research environment.

• Total of two active phase‑1 investigations
• Single investigator leading both studies
• No dedicated research sites, trials conducted at affiliated hospitals
• Emphasis on safety, dosing, and early efficacy signals

Continued patient enrollment will support early‑stage discovery and lay the groundwork for future multi‑center collaborations.